Ferring inks $500M deal with Royalty Pharma on new bladder cancer gene therapy
Fierce Pharma
AUGUST 24, 2023
Royalty Pharma has built a niche by finding innovative products pre- and post-approval from companies that need an infusion of cash in exchange for future royalties. Royalty Pharma has signed a deal with Ferring Pharmaceuticals to collect royalties on bladder cancer drug Adstiladrin.
Let's personalize your content